Roche’s Vabysmo Could Nab Nearly One Third of Regeneron’s Eylea Patients

Roche’s intraocular injectable Vabysmo has made impressive gains since its approval in January, cranking up the heat on Regeneron’s Eylea. Vabysmo treats wet-age macular degeneration (AMD) and diabetic macular edema (DME), preserving vision for up to four months per treatment. This stands in contrast with Eylea, which is injected every two months. As a result, a survey of retinal specialist suggests that Vabysmo could eat up to 30% of Eylea’s market share in the next 12 months.

According to Kevin Dunleavy, “Regeneron is working on a higher-dose version of Eylea that could be given every four months. But the best case for approval is the second half of 2023. Meanwhile, Vabysmo has ‘considerable time to entrench,’ Evercore’s Schimmer writes. It’s yet to be determined if high-dose Eylea can ‘deliver results that are more compelling than Vabysmo,’ Schimmer wrote, but that ‘seems unlikely.’”

To learn more, click here.

(Source: Fierce Pharma, June 13^th, 2022)